Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer
A Pilot Study of the Biologic Efficacy and Safety of the Addition of Celecoxib to a Program of Induction Chemotherapy and Neo-Adjuvant Chemo-Radiotherapy for the Treatment of Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy and radiation therapy together with celecoxib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving irinotecan and cisplatin together with radiation therapy with or without celecoxib works in treating patients with stage II, stage III, or stage IV esophageal cancer.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
OBJECTIVES:
Primary
- To measure the rates of cellular apoptosis and proliferation at baseline and during chemoradiotherapy with and without celecoxib using biopsy samples from patients with stage II, III, or IV esophageal cancer.
- To determine if an acceptable rate of pathologic complete remission can be achieved in a subset of patients with potentially resectable esophageal cancer.
Secondary
- To assess the safety of the addition of daily celecoxib to chemoradiotherapy.
- To estimate the median overall survival in a subset of patients with resectable disease.
- To quantitate expression of cyclooxygenase (COX)-2 and formation of prostaglandin E2 (PGE2) in patients with esophageal cancer.
- To assess the ability of celecoxib to decrease formation of PGE2 in tumor tissue by measuring pre- and post-treatment tumor concentrations of PGE2.
- To quantitate downstream effects of inhibition of COX-2 function in the setting of treatment with chemotherapy.
- To measure the radiographic response rate in patients with unresectable esophageal cancer.
OUTLINE: This is a multicenter study. Patients are sequentially enrolled into 1 of 2 treatment groups.
- Group 1: Patients receive cisplatin IV over 1 hour and irinotecan hydrochloride IV over 90 minutes on days 1, 8, 22, 29, 43, 50, 64, and 71. Patients also undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 43.
- Group 2: Patients receive chemoradiotherapy as in group 1. Patients also receive oral celecoxib twice daily beginning 3 days before the initiation of chemotherapy and continuing until the completion of chemoradiotherapy.
In both groups, patients with potentially resectable disease undergo surgery no more than 12 weeks after completion of chemoradiotherapy.
Endoscopic tumor biopsy specimens are collected at baseline and on day 3 of radiotherapy. Samples are analyzed for cyclooxygenase (COX)-2 gene and protein expression; PGE2 secretion; apoptotic activity; caspase-3 activation; cytochrome c translocation; VEGF mRNA quantitation; and cellular proliferation. Laboratory techniques used include RT-PCR, IHC, enzyme immunoassay, TUNEL assay, colorimetric assay, and northern blotting.
After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 34 patients (8-10 in group 1 and 24 in group 2) will be accrued for this study.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
DISEASE CHARACTERISTICS:
Biopsy proven squamous cell carcinoma or adenocarcinoma of the esophagus
- Lesions including the gastroesophageal junction allowed provided the tumor involves less than 2 cm of gastric cardia
Meets 1 of the following criteria:
Clinical stage II, III, or IV disease AND planning to receive chemoradiotherapy either for preoperative or palliative indications (group 1)
- Suitable candidate for bimodality (palliative intent) or trimodality (curative intent) therapy
Clinical stage II or III disease AND candidate to receive chemoradiotherapy for preoperative indication followed by planned esophagectomy or esophagogastrectomy (group 2)
- Suitable candidate for trimodality (curative intent) therapy
- No tracheoesophageal fistula on bronchoscopy
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy > 3 months (group 1)
- Not pregnant
- Adequate nutrition
- WBC ≥ 4,000/μL
- ANC ≥ 1,500/μL
- Platelet count ≥ 100,000/μL
- Serum creatinine ≤ 1.5 mg/dL
- Bilirubin ≤ 1.5 mg/dL
No other prior or concurrent malignancy other than curatively treated carcinoma in situ of the cervix; localized prostate cancer that was previously treated with local therapy more than 2 years ago with a PSA of less than 4 ng/mL; basal cell carcinoma of the skin; or superficial transitional cell carcinoma of the bladder
- Patients who have had a prior malignancy are eligible if they have been free of disease for ≥ 5 years
- No serious medical or psychiatric illnesses that would preclude giving informed consent or otherwise limit survival to less than 2 years
- No history of known NSAID-induced gastrointestinal bleeding
- No current peptic ulcer disease
- No active coronary artery disease
- No myocardial infarction or cerebrovascular accident within the past 3 months
- No history of refractory congestive heart failure or cardiomyopathy
PRIOR CONCURRENT THERAPY:
- More than 1 week since prior major surgery (group 1)
- More than 2 weeks since prior major surgery (group 2)
- No prior chemotherapy or radiotherapy
More than 30 days since prior cyclooxygenase-2 inhibitors (selective or non-selective), including, but not limited to, any of the following:
- Acetylsalicylic acid (aspirin)
- Piroxicam
- Diclofenac
- Meloxicam
- Indomethacin
- Fenoprofen
- Sulindac
- Flurbiprofen
- Tolmetin
- Ibuprofen
- Celecoxib
- Ketoprofen
- Rofecoxib
- Ketoprofen ER
- Valdecoxib
- Naproxen
- Meclofenamate
- Oxaprozin
- Mefenamic acid
- Etodolac
- Nabumetone
- Ketorolac
- No concurrent seizure medications
- No concurrent amifostine or other such agents
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Cohort 1
Induction chemotherapy and chemoradiation without celecoxib
|
65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Ostatní jména:
Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
Ostatní jména:
4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
|
|
Experimentální: Cohort 2
Induction chemotherapy and chemoradiation with celecoxib
|
65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Ostatní jména:
Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
Ostatní jména:
4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Rates of cellular apoptosis and proliferation
Časové okno: 5 weeks
|
Measure the rates of cellular apoptotis and proliferation in esophageal cancers from biopsy samples pre-study and during chemoradiation with and without celecoxib therapy
|
5 weeks
|
|
Rate of pathologic complete remission in patients with resectable disease
Časové okno: 4 years
|
To determine if an acceptable rate of pathologic complete remissions can be achieved in a cohort of patients with potentially resectable esophageal carcinoma
|
4 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of subjects experiencing adverse events
Časové okno: 30 days post radiation
|
Adverse events/toxicity will graded per the CTCAE criteria
|
30 days post radiation
|
|
Median overall survival of patients with resectable disease
Časové okno: 4 years
|
Follow up for survival will occur at 3 month intervals during the first two years, then every 6 months during years 3 and 4.
|
4 years
|
|
Formation of prostaglandin E2 (PGE2) in tumor tissue
Časové okno: 12 weeks
|
The ability of celecoxib to decrease formation of prostaglandin E2 (PGE2) in tumor tissue will be analyzed using a Wilcoxon signed rank test on the difference (log scale) of the pre- and post-treatment tumor concentrations of PGE2
|
12 weeks
|
|
Downstream effects of inhibition of cyclooxygenase 2 function
Časové okno: 12 weeks
|
A difference in location of the mRNA expression of the two cohorts will be tested for using the Wilcoxon rank sum test.
A difference in the immunohistochemistry staining of the two cohorts will be tested for using polytomous logistic regression
|
12 weeks
|
|
Response Rate
Časové okno: 4 years
|
Radiographic repsonse will be measured using RECIST critera in patients with unresectable esophageal cancer.
|
4 years
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Bert H. O'Neil, MD, UNC Lineberger Comprehensive Cancer Center
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Nemoci trávicího systému
- Novotvary
- Novotvary podle místa
- Gastrointestinální novotvary
- Novotvary trávicího systému
- Gastrointestinální onemocnění
- Novotvary hlavy a krku
- Nemoci jícnu
- Novotvary jícnu
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Agenti periferního nervového systému
- Inhibitory enzymů
- Analgetika
- Agenti smyslového systému
- Protizánětlivé látky, nesteroidní
- Analgetika, nenarkotika
- Protizánětlivé látky
- Antirevmatika
- Inhibitory cyklooxygenázy
- Antineoplastická činidla
- Inhibitory topoizomerázy
- Inhibitory cyklooxygenázy 2
- Inhibitory topoizomerázy I
- Celekoxib
- Irinotekan
Další identifikační čísla studie
- LCCC 0203
- CDR0000561610 (Jiný identifikátor: NCI PDQ identifier)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na CPT- 11
-
Daiichi Sankyo Co., Ltd.DokončenoMetastatický kolorektální karcinomJaponsko
-
Kazuhiko YoshimatsuHuman Genome Center, Institute of Medical Science, University of TokyoDokončenoKolorektální karcinomJaponsko
-
University of California, San FranciscoDokončenoGlioblastom | Gliosarkom | Anaplastický astrocytom | Anaplastický oligodendrogliomSpojené státy
-
JenKem Technology Co., Ltd.Dokončeno
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktivní, ne náborRecidivující glioblastom | Recidivující maligní gliom | Recidivující gliom III. stupně WHO | Recidivující gliosarkom | Recidivující anaplastický astrocytom | Recidivující anaplastický oligoastrocytom | Recidivující anaplastický oligodendrogliomSpojené státy
-
National Cancer Institute (NCI)DokončenoRefrakterní maligní solidní novotvar | Pineoblastom | Recidivující maligní solidní novotvar | Recidivující meduloblastom | Recidivující neuroblastom | Recidivující rabdomyosarkom | Refrakterní meduloblastom | Refrakterní neuroblastom | Refrakterní rabdomyosarkom | Embryonální nádor centrálního nervového systému... a další podmínkySpojené státy, Kanada
-
Assiut UniversityAktivní, ne nábor
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)StaženoRecidivující Ewingův sarkom | Metastatický Ewingův sarkomSpojené státy
-
Grupo Hospital de MadridDokončenoRakovina konečníkuŠpanělsko
-
National Cancer Institute (NCI)Aktivní, ne náborSolidní novotvar pro dospěléSpojené státy